Skip to main content

Taxane-naïve metastatic castration-resistant prostate cancer, the PSMAfore trial

Intervista a Christopher Sweeney By 23 Ottobre 2023No Comments

PSMAfore trial met its primary endpoint, demonstrating an improvement in radiographic progression-free survival (rPFS) with the prostate-specific membrane antigen (PSMA)-targeted radioligand 177Lu-PSMA-617 compared with androgen receptor pathway inhibitor (ARPI) switch in metastatic castration-resistant prostate cancer (mCRPC) progressing on prior ARPI therapy. We met Christopher Sweeney (Director of the South Australian immunoGENomics Cancer Institute – SAiGENCI at the University of Adelaide) just after the Presidential Session at the ESMO Congress 2023 in Madrid.